Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Phathom Pharmaceuticals Inc (NQ: PHAT )

11.94 +1.13 (+10.45%)
Streaming Delayed Price Updated: 10:58 AM EDT, Aug 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 378,272
Open 11.50
Bid (Size) 11.92 (1)
Ask (Size) 11.98 (2)
Prev. Close 10.81
Today's Range 11.11 - 12.06
52wk Range 6.065 - 17.02
Shares Outstanding 43,614,075
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
From Phathom Pharmaceuticals
Via GlobeNewswire

Performance

YTD
+30.21%
+30.21%
1 Month
+14.48%
+14.48%
3 Month
+18.22%
+18.22%
6 Month
+65.15%
+65.15%
1 Year
-18.89%
-18.89%

More News

Read More
Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024
From Phathom Pharmaceuticals
Via GlobeNewswire
Preview: Phathom Pharmaceuticals's Earnings
Via Benzinga
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
From Phathom Pharmaceuticals
Via GlobeNewswire
Ready for Quick Gains? 7 Top Short-Squeeze Stocks to Watch Now
Via InvestorPlace
Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze
Via InvestorPlace
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
The 3 Best Healthcare Stocks to Buy in May 2024
Via InvestorPlace
PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
From Phathom Pharmaceuticals
Via GlobeNewswire
PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
From Phathom Pharmaceuticals
Via GlobeNewswire
Walmart Posts Upbeat Earnings, Joins Armstrong World Industries, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For March 7, 2024
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
From Phathom Pharmaceuticals
Via GlobeNewswire
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Phathom Pharmaceuticals
Via GlobeNewswire
"Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.